NGNE PE Ratio & Valuation,Is NGNE Overvalued

NGNE Relative Valuation

NGNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NGNE is overvalued; if below, it's undervalued.

Historical Valuation

Neurogene Inc (NGNE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.08. The fair price of Neurogene Inc (NGNE) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：20.80

Fair

-4.20

0.00

EV/EBITDA

Neurogene Inc. (NGNE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.63

EV/EBIT

Neurogene Inc. (NGNE) has a current EV/EBIT of -0.63. The 5-year average EV/EBIT is -2.72. The thresholds are as follows: Strongly Undervalued below -7.88, Undervalued between -7.88 and -5.30, Fairly Valued between -0.15 and -5.30, Overvalued between -0.15 and 2.43, and Strongly Overvalued above 2.43. The current Forward EV/EBIT of -0.63 falls within the Historic Trend Line -Fairly Valued range.

0.00

Neurogene Inc. (NGNE) has a current PS of 0.00. The 5-year average PS is 117.21. The thresholds are as follows: Strongly Undervalued below -520.91, Undervalued between -520.91 and -201.85, Fairly Valued between 436.27 and -201.85, Overvalued between 436.27 and 755.33, and Strongly Overvalued above 755.33. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.46

P/OCF

Neurogene Inc. (NGNE) has a current P/OCF of -3.46. The 5-year average P/OCF is -4.99. The thresholds are as follows: Strongly Undervalued below -9.37, Undervalued between -9.37 and -7.18, Fairly Valued between -2.80 and -7.18, Overvalued between -2.80 and -0.62, and Strongly Overvalued above -0.62. The current Forward P/OCF of -3.46 falls within the Historic Trend Line -Fairly Valued range.

-3.24

P/FCF

Neurogene Inc. (NGNE) has a current P/FCF of -3.24. The 5-year average P/FCF is -4.41. The thresholds are as follows: Strongly Undervalued below -8.20, Undervalued between -8.20 and -6.31, Fairly Valued between -2.52 and -6.31, Overvalued between -2.52 and -0.62, and Strongly Overvalued above -0.62. The current Forward P/FCF of -3.24 falls within the Historic Trend Line -Fairly Valued range.

Neurogene Inc (NGNE) has a current Price-to-Book (P/B) ratio of 1.16. Compared to its 3-year average P/B ratio of 2.01 , the current P/B ratio is approximately -42.19% higher. Relative to its 5-year average P/B ratio of 2.01, the current P/B ratio is about -42.19% higher. Neurogene Inc (NGNE) has a Forward Free Cash Flow (FCF) yield of approximately -24.20%. Compared to its 3-year average FCF yield of -20.49%, the current FCF yield is approximately 18.11% lower. Relative to its 5-year average FCF yield of -20.49% , the current FCF yield is about 18.11% lower.

1.16

P/B

Median3y

2.01

Median5y

2.01

-24.20

FCF Yield

Median3y

-20.49

Median5y

-20.49

Competitors Valuation Multiple

The average P/S ratio for NGNE's competitors is 8165.24, providing a benchmark for relative valuation. Neurogene Inc Corp (NGNE) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NGNE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NGNE in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Neurogene Inc (NGNE) currently overvalued or undervalued?

What is Neurogene Inc (NGNE) fair value?

NGNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neurogene Inc (NGNE) is between NaN to NaN according to relative valuation methord.

How does NGNE's valuation metrics compare to the industry average?

The average P/S ratio for NGNE's competitors is 8165.24, providing a benchmark for relative valuation. Neurogene Inc Corp (NGNE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Neurogene Inc (NGNE) as of Dec 15 2025?

As of Dec 15 2025, Neurogene Inc (NGNE) has a P/B ratio of 1.16. This indicates that the market values NGNE at 1.16 times its book value.

What is the current FCF Yield for Neurogene Inc (NGNE) as of Dec 15 2025?

As of Dec 15 2025, Neurogene Inc (NGNE) has a FCF Yield of -24.20%. This means that for every dollar of Neurogene Inc’s market capitalization, the company generates -24.20 cents in free cash flow.

What is the current Forward P/E ratio for Neurogene Inc (NGNE) as of Dec 15 2025?

As of Dec 15 2025, Neurogene Inc (NGNE) has a Forward P/E ratio of -4.20. This means the market is willing to pay $-4.20 for every dollar of Neurogene Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neurogene Inc (NGNE) as of Dec 15 2025?

As of Dec 15 2025, Neurogene Inc (NGNE) has a Forward P/S ratio of 0.00. This means the market is valuing NGNE at $0.00 for every dollar of expected revenue over the next 12 months.

NGNE Valuation